Bei Zhou

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

Ronald van Vollenhoven, Bevra H. Hahn, George C. Tsokos et al. · The Lancet · 2018 · 317 citations

Rheumatology, Il-23 Inhibitor, Autoimmune Disease +13

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

Atul Deodhar, Philip Helliwell, Wolf‐­Henning Boehncke et al. · The Lancet · 2020 · 307 citations

Rheumatology, Autoimmune Disease, Placebo-controlled Phase 3 +11

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial

Arthur Kavanaugh, Gerald G. Krueger, Anna Beutler et al. · Annals of the Rheumatic Diseases · 2006 · 193 citations · Full text

Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).

Christian Antoni, Arthur Kavanaugh, Désirée van der Heijde et al. · PubMed · 2008 · 155 citations

Silibinin Protects Against Isoproterenol-Induced Rat Cardiac Myocyte Injury Through Mitochondrial Pathway After Up-regulation of SIRT1

Bei Zhou, WU Li-jun, Linhao Li et al. · Journal of Pharmacological Sciences · 2006 · 106 citations · Full text